Medexus Pharmaceuticals Inc. (TSE:MDP) Given Average Rating of “Strong Buy” by Brokerages

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been assigned an average rating of “Strong Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is C$5.58.

MDP has been the subject of several recent analyst reports. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research note on Monday, September 30th. Stifel Nicolaus raised their target price on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a research report on Wednesday, January 8th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd.

Medexus Pharmaceuticals Price Performance

Shares of MDP stock opened at C$4.29 on Tuesday. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$4.60. The firm has a market capitalization of C$105.23 million, a price-to-earnings ratio of 85.80 and a beta of 1.96. The business has a 50 day simple moving average of C$3.04 and a 200 day simple moving average of C$2.66.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.